Cargando…

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES

BACKGROUND: BRAF mutations occur in 50% of melanoma patients. Targeted agents – BRAF and MEK inhibitors and immunotherapy improve survival of melanoma patients with BRAF mutations. These agents have intracranial efficacy as shown in clinical trials. However, the efficacy of immunotherapies (immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauko, Adam, Sagar, Soumya, Barnett, Addison, Wei, Wei, Chao, Samuel, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213464/ http://dx.doi.org/10.1093/noajnl/vdz014.053

Ejemplares similares

THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-02. IMPACT OF SYSTEMIC THERAPY IN MELANOMA BRAIN METASTASIS
por: Sagar, Soumya, et al.
Publicado: (2019)

THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

THER-16. EFFICACY OF UPFRONT IMMUNE CHECKPOINT INHIBITORS IN LUNG CANCER BRAIN METASTASIS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-14. INFLUENCE OF CLINICAL PARAMETERS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (NSCLCBM)
por: Lauko, Adam, et al.
Publicado: (2019)

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

TRLS-05. EARLY RESULTS FROM A PROSPECTIVE PHASE I/II DOSE ESCALATION STUDY OF NEOADJUVANT RADIOSURGERY FOR BRAIN METASTASES
por: Murphy, Erin, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

RADI-25. REPEAT STEREOTACTIC RADIOSURGERY FOR RECURRENT BRAIN METASTASES
por: Krivosheya, Daria, et al.
Publicado: (2019)

RADI-35. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS
por: Kotecha, Rupesh, et al.
Publicado: (2019)

First follow‐up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases
por: Sharma, Mayur, et al.
Publicado: (2017)

Medical management of brain metastases
por: Lauko, Adam, et al.
Publicado: (2020)

An Excellent Clinical Outcome with Stereotactic Radiosurgery in a Geriatric Patient with Multiple and Recurrent Brain Metastases
por: Thapa, Bicky, et al.
Publicado: (2017)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2019)

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
por: Tatineni, Vineeth, et al.
Publicado: (2023)

THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES
por: Vincent, Benjamin, et al.
Publicado: (2019)

Targeted therapy of brain metastases: latest evidence and clinical implications
por: Di Lorenzo, Rodica, et al.
Publicado: (2017)

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
por: Ahluwalia, Manmeet, et al.
Publicado: (2020)

THER-04. THE USE OF AN ADENOSINE A2 AGONIST TO IMPROVE THE PREVENTION AND TREATMENT OF BRAIN METASTASES
por: Grossman, Stuart, et al.
Publicado: (2019)

Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression
por: Alban, Tyler J., et al.
Publicado: (2020)

Veterinary Medicines: Ther Actions and Uses
Publicado: (1883)

Novel Therapeutic Approaches in Neoplastic Meningitis
por: Khosla, Atulya Aman, et al.
Publicado: (2022)

THER-15. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELL THERAPY FOR BRAIN METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2019)

THER-07. DEVELOPMENT OF A NEW MOLECULAR PREDICTOR FOR RISK OF BRAIN METASTASES AND EFFICACY OF TARGETED THERAPY IN MELANOMA
por: Colman, Howard, et al.
Publicado: (2019)

Report by ther Chairman of the Scientific Policy Committee
Publicado: (1959)

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases
por: Tonse, Raees, et al.
Publicado: (2021)

Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins
por: Grabowski, Matthew M., et al.
Publicado: (2023)

TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh, et al.
Publicado: (2019)

Laser interstitial thermal therapy for brain metastases
por: Srinivasan, Ethan S, et al.
Publicado: (2021)

First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
por: Dhawan, Andrew, et al.
Publicado: (2022)

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh P, et al.
Publicado: (2020)

The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
por: Billena, Cole, et al.
Publicado: (2023)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

P-THER-09: Endoscopic ultrasound-guided pelvic abscess drainage
por: Harwani, Yogesh, et al.
Publicado: (2017)

THER-04. IS THERE A ROLE FOR CANNABIDIOL IN THE TREATMENT OF CHILDHOOD BRAIN TUMOURS?
por: Lockwood, George, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_71kn80upfripld71upilc60vra